Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
As poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with the deficiency of DNA double-strand (DSB) break repair by homologous recombination (HR), PARP inhibitors (PARPi) are currently used to treat breast cancers with mutated <i>BRCA</i>1/2 HR factors. Unfortunately, th...
Main Authors: | Camille Franchet, Jean-Sébastien Hoffmann, Florence Dalenc |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/16/4132 |
Similar Items
-
Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
by: Young-Hwa Soung, et al.
Published: (2023-10-01) -
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
by: Nizialek E, et al.
Published: (2020-09-01) -
Homologous recombination proficiency in ovarian and breast cancer patients
by: Justin Fortune Creeden, et al.
Published: (2021-10-01) -
Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Xu Liu, et al.
Published: (2021-10-01) -
Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
by: Xuan-zhang Huang, et al.
Published: (2020-06-01)